Welcome to Adaptimmune Ltd
Founded in July 2008, Adaptimmune is focused on the use of T cell therapy to treat cancer and infectious disease. It aims to utilise the body’s own machinery – the T cell – to target and destroy cancerous or infected cells by using engineered, increased affinity T cell receptor proteins (TCRs) as a means of strengthening natural patient T cell responses. Adaptimmune holds an exclusive licence to the use of this unique T cell receptor engineering technology in adoptive T cell therapy from its sister company, Immunocore Ltd. (formerly Avidex/MediGene). It has already opened a clinical trial with the technology in HIV in the US, with plans to open a cancer trial in late 2010.
Backed by private investors and located alongside Immunocore Ltd. in its South Oxfordshire facilities, Adaptimmune operates a virtual business model with a small, focused management and scientific team and strong academic collaborations for rapid translation to the clinic.
